Meeting Banner
Abstract #4606

MDCT outperforms gadoxetate-enhanced MRI in differentiating stroma-rich tumors from hepatocellular carcinomas developing in patients with chronic liver diseases

Kengo Yoshimitsu1

1Radiology, Fukuoka University, Fukuoka, Japan

Consecutive 179 patients with chronic liver diseases who underwent gadoxetate enhanced-MRI and MDCT firstly developed hypervascular liver masses were retrospectively recruited, and 14 stroma-rich tumors (SRT), such as intrahepatic cholangiocellular carcinoma, and 165 hepatocellular carcinoma (HCC) were found. Using rim enhancement, and target sign on DWI, which were confirmed to favor SRT over HCC by multivariate analysis on gadoxetate-enhanced MRI, 71% sensitivity and 97% specificity were obtained, however, MDCT provided almost 100% accuracy when delayed or prolonged enhancement was considered signs suggesting SRT. For diagnosing SRT, MDCT outperforms gadoxetate-enhanced MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here